We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.
WE FOCUS ON UNMET MEDICAL NEEDS IN CHRONIC DISEASES
Currently available treatments for many neurodegenerative diseases aim to manage symptoms, and do not stop disease progression. As a result, neurodegenerative diseases often lead to a reduced quality of life. Better treatments for these diseases are needed to give patients healthier, happier, and longer lives. We aim to develop therapeutic and preventative treatments that address the root causes of neurodegenerative diseases: an ethos inspired by the impact of vaccines on health and society worldwide.
OUR APPROACH
Our novel approach, Specific Active ImmunoTherapy (SAIT), stimulates the body’s own immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT was developed using our AFFITOME technology, which allows for optimization of immune responses against pathogenic forms of proteins, and it may permit targeting of multiple pathogenic proteins in one disease setting. SAIT is designed to induce a long-lasting immune response, which we anticipate will translate into effective quarterly/twice-yearly dosing.
OUR PIPELINE
We have a broad portfolio of immunotherapy candidates, which are currently in clinical trials or preclinical development for chronic diseases, including Parkinson’s Disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington's disease.
OUR TEAM
We are a passionate and dedicated team with a proven track record of making ground-breaking scientific discoveries and developing novel therapies. Our exciting work spans early discovery, preclinical advancement of SAIT and monoclonal antibody drug candidates, and translation of science into clinical development.
Please follow us on LinkedIn and visit www.affiris.com.
WE FOCUS ON UNMET MEDICAL NEEDS IN CHRONIC DISEASES
Currently available treatments for many neurodegenerative diseases aim to manage symptoms, and do not stop disease progression. As a result, neurodegenerative diseases often lead to a reduced quality of life. Better treatments for these diseases are needed to give patients healthier, happier, and longer lives. We aim to develop therapeutic and preventative treatments that address the root causes of neurodegenerative diseases: an ethos inspired by the impact of vaccines on health and society worldwide.
OUR APPROACH
Our novel approach, Specific Active ImmunoTherapy (SAIT), stimulates the body’s own immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT was developed using our AFFITOME technology, which allows for optimization of immune responses against pathogenic forms of proteins, and it may permit targeting of multiple pathogenic proteins in one disease setting. SAIT is designed to induce a long-lasting immune response, which we anticipate will translate into effective quarterly/twice-yearly dosing.
OUR PIPELINE
We have a broad portfolio of immunotherapy candidates, which are currently in clinical trials or preclinical development for chronic diseases, including Parkinson’s Disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington's disease.
OUR TEAM
We are a passionate and dedicated team with a proven track record of making ground-breaking scientific discoveries and developing novel therapies. Our exciting work spans early discovery, preclinical advancement of SAIT and monoclonal antibody drug candidates, and translation of science into clinical development.
Please follow us on LinkedIn and visit www.affiris.com.
Location: Austria, Vienna
Employees: 51-200
Total raised: $45.05M
Founded date: 2003
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.06.2016 | - | $11.11M | - |
| 09.11.2011 | - | $33.94M | - |
Mentions in press and media 8
| Date | Title | Description |
| 28.07.2021 | AC Immune acquires Parkinson’s disease vaccine candidate and equity investment | Parkinson's disease is causally linked to pathological aggregation and deposition of a-syn, a drug target that has been validated in clinical studies using monoclonal antibodies. Austrian clinical-stage biopharmaceutical company Affiris dev... |
| 27.04.2021 | PRESS RELEASE : AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Con... | DGAP-News: AFFiRiS AG / Key word(s): Conference/Study AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Confe... |
| 27.04.2021 | AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference | DGAP-News: AFFiRiS AG / Key word(s): Conference/Study AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Confe... |
| 27.04.2021 | Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference | Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathologyHuman mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral ... |
| 21.06.2020 | The Lancet Neurology publishes positive results of AFFiRiS’ Phase 1 trial with PD01A in Parkinson’s disease patients | Repeated immunisation with PD01A is safe and well-tolerated over an extended time period Active immunisation with PD01A resulted in a substantial aSyn-specific antibody response and memory effect This antibody response was associated with a... |
| 28.06.2016 | Therapeutic Peptide Vaccine Developer Affiris Raises €10M | Affiris AG, a Vienna, Austria-based developer of therapeutic peptide vaccines against chronic diseases, raised an additional €10m in funding. Backers included Santo Holding – the family office of the Strüngmann family – ,the MIG Funds advis... |
| 24.06.2016 | AFFiRiS AG successfully raises €10m equity financing | AFFiRiS AG successfully raises €10m equity financing 06-24-2016 10:27 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: AFFiRiS AG / PR Agency: PR&D • € 10m additional capital raised • Strengthened manage... |
| 09.11.2011 | AFFiRiS Raises €25M in Equity Funding | AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer’s disease, Atherosclerosis, Parkinson’s disease, hypertension and several other conditions, has raised €25m in equity funding. Backers include Santo... |